

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

ENZO BIOCHEM INC  
Form 11-K  
July 12, 2004

=====

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----

FORM 11-K

ANNUAL REPORT  
PURSUANT TO SECTION 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

(MARK ONE)

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2003

OR

TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934 [NO FEE REQUIRED].

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER 001-09974

-----

Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan

(Full title of the plan and the address of the plan, if different from that  
of the issuer named below:)

ENZO BIOCHEM, INC., 60 EXECUTIVE BOULEVARD, FARMINGDALE, NY 11735

(Name of issuer of the securities held pursuant to the plan and the address  
of its principal executive office)

=====

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN

TABLE OF CONTENTS

REPORT OF WATSON RICE LLP  
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ..... F-1

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

FINANCIAL STATEMENTS FOR THE YEARS ENDED  
DECEMBER 31, 2003 AND 2002:

Statements of Net Assets Available for Benefits ..... F-2  
Statement of Changes in Net Assets Available for Benefits..... F-3  
Notes to Financial Statements ..... F-4

SUPPLEMENTAL SCHEDULE FOR THE YEAR ENDED  
DECEMBER 31, 2003:

Schedule H, Item 4i --  
Schedule of Assets Held at End of Year ..... F-8

REPORT OF AUDREY WALLACH, CPA, INDEPENDENT AUDITORS ..... F-10

FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2002

STATEMENT OF NET ASSETS  
AVAILABLE FOR BENEFITS ..... F-11  
STATEMENT OF CHANGES IN NET ASSETS  
AVAILABLE FOR BENEFITS ..... F-12  
NOTES TO FINANCIAL STATEMENTS ..... F-13  
SCHEDULE OF NON-EXEMPT TRANSACTIONS ..... F-17

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Trustees of  
Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan

We have audited the accompanying statement of net assets available for benefits of Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan (the "Plan") as of December 31, 2003, and the related statement of changes in net assets available for benefits for the year ended December 31, 2003. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audit. The financial statements of Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan as of December 31, 2002 were audited by other auditors whose report dated September 20, 2003 expresses an unqualified opinion on those statements.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2003 and the changes in net assets available for benefits for the

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

year ended December 31, 2003 in conformity with accounting principles generally accepted in the United States of America.

Our audit was conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplemental schedule of assets held for investment purposes at the end of the year, is presented for the purpose of additional analysis and is not a required part of the basic financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. The supplemental schedule is the responsibility of the Plan's management. The supplemental schedule has been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

WATSON RICE LLP

New York, New York  
July 9, 2004

F-1

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN

Statements of Net Assets Available for Benefits

December 31,

|                                   | 2003        | 2002        |
|-----------------------------------|-------------|-------------|
|                                   | -----       | -----       |
| ASSETS                            |             |             |
| Investments at Fair Value:        |             |             |
| Mutual funds                      | \$6,213,531 | \$4,409,225 |
| Common stock                      | 1,685,349   | 1,031,265   |
|                                   | -----       | -----       |
|                                   | 7,898,880   | 5,440,490   |
|                                   | -----       | -----       |
| Receivables:                      |             |             |
| Employer's contributions          | 282,239     | 257,450     |
| Participants' contributions       | 480         | -           |
|                                   | -----       | -----       |
|                                   | 282,719     | 257,450     |
|                                   | -----       | -----       |
| Loans receivable -- participants  | 235,312     | 174,741     |
|                                   | -----       | -----       |
| TOTAL ASSETS                      | 8,416,911   | 5,872,681   |
|                                   | -----       | -----       |
| NET ASSETS AVAILABLE FOR BENEFITS | \$8,416,911 | \$5,872,681 |
|                                   | =====       | =====       |

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

See notes to financial statements

F-2

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

FOR THE YEAR ENDED DECEMBER 31, 2003

|  |           |             |
|--|-----------|-------------|
| Additions to Net Assets Attributed to:               |           |             |
| Participants' contributions                          |           | \$ 704,353  |
| Employer's contributions                             |           | 284,609     |
| Rollovers  |           | 24,698      |
| Interest on loans to participants                    |           | 9,471       |
| Net appreciation in fair value of investments:       |           |             |
| Mutual funds   | 1,242,258 |             |
| Common stock   | 439,811   | 1,682,069   |
|  | -----     | -----       |
| Total Additions                                      |           | 2,705,200   |
|  |           | -----       |
| Deductions from Net Assets Attributed to:            |           |             |
| Benefits paid to participants                        |           | 130,683     |
| Administrative expenses                              |           | 30,287      |
|  |           | -----       |
| Total Deductions                                     |           | 160,970     |
|  |           | -----       |
| Net increase in net assets                           |           | 2,544,230   |
| Net Assets Available for Benefits, Beginning of Year |           | 5,872,681   |
|  |           | -----       |
| Net Assets Available for Benefits, End of Year       |           | \$8,416,911 |
|  |           | =====       |

See notes to financial statements.

F-3

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2003 AND 2002

NOTE 1. PLAN DESCRIPTION

The following description of the Enzo Biochem, Inc., Salary Reduction

## Edgar Filing: ENZO BIOCHEM INC - Form 11-K

Profit-Sharing Plan (the "Plan") provides only general information. Participants should refer to the Plan Agreement, as amended, for a more complete description of the Plan's provisions.

### GENERAL

The Plan is a defined contribution plan covering all eligible full time employees of Enzo Biochem, Inc., Enzo Clinical Labs, Inc., Enzo Therapeutics, Inc. and Enzo Life Sciences (the "Companies") who have completed three months of service and have attained age twenty-one.

The Plan is subject to the provisions of the Employment Retirement Income Security Act of 1974 (ERISA).

### CONTRIBUTIONS

Eligible employees can elect to defer up to 17% of their compensation, as defined by the Plan, limited to the maximum for each year (\$12,000 in 2003) permitted by the Internal Revenue Code. In addition, the Companies will contribute to the plan a discretionary matching contribution equal to 50% of the employees' 401(k) contribution, not to exceed 10% of the employee's annual compensation. Participants who have completed a year of service during the plan year and are actively employed as of the last day of the plan year shall be deemed eligible to share in the matching contribution for the year. In 2003 and 2002 the total matching contributions were \$282,239 and \$257,450, respectively, in the form of Enzo Biochem Inc. company stock.

F-4

## ENZO BIOCHEM, INC. SALARY REDUCTION PROFIT SHARING PLAN

### NOTES TO FINANCIAL STATEMENTS - CONTINUED

#### NOTE 1. PLAN DESCRIPTION - CONTINUED

##### PARTICIPANTS' ACCOUNTS

Contributions are invested in a choice of sixteen mutual funds and the common stock of Enzo Biochem, Inc. (see Note 7). Contribution selections are designated by the participants. Each participant's account is credited with the participant's contribution and allocations of (a) the Companies contributions and (b) Plan earnings, and charged with an allocation of administrative expenses. Allocations are based on participant compensation or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

##### VESTING

Participants' contributed funds arising from salary reductions and the earnings thereon, are fully vested at all times. Vesting in the Companies' matching contribution and earnings thereon, is ratable over four years of service. Forfeitures are allocated among participants eligible to share for a plan year.

##### LOANS TO PARTICIPANTS

## Edgar Filing: ENZO BIOCHEM INC - Form 11-K

Participants may borrow from their 401(k) accounts a minimum of \$1,000 up to a maximum of 50% of their vested account balance or \$50,000. Participants are entitled to borrow from their account for a maximum loan term of five years unless the proceeds are used to acquire a principal residence in which case it may exceed 5 years. The loans are secured by the participant's vested account balance and bear a reasonable rate of interest. Principal and interest is paid ratably through payroll deductions.

### PAYMENT OF BENEFITS

On termination of service due to death, disability or retirement, participants may elect to receive an amount equal to the value of the participants' vested interest in their account in either a lump sum amount or in various annuity options. For termination of service due to other reasons, a participant may receive the value of the vested interest in their account as a lump sum distribution. Benefits are payable in the form of cash or property.

F-5

### ENZO BIOCHEM, INC. SALARY REDUCTION PROFIT SHARING PLAN

#### NOTES TO FINANCIAL STATEMENTS - CONTINUED

#### NOTE 1. PLAN DESCRIPTION - CONTINUED

##### OPERATING EXPENSES

Certain operating expenses of the Plan are absorbed by the Plan Sponsor.

#### NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Plan's financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and under the accrual basis method of accounting.

The Plan's investments are stated at fair value except for its benefit responsive investment contract which is valued at contract value (Note 4). Investment earnings are reinvested in the respective funds. Investment earnings include the Plan's proportionate share of interest, dividends, realized gains and losses on the disposal of investments, and appreciation or depreciation in the fair value of the underlying investments comprising the respective mutual funds. All purchases and sales are recorded on a trade date basis.

The Plan presents in the statement of changes in net asset available for benefits, the net appreciation in fair value of its investments, which consists of the realized gains or losses and the unrealized appreciation (depreciation) on those investments.

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts and disclosures in the financial statements. Actual results could differ from those estimates.

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

F-6

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN

NOTES TO FINANCIAL STATEMENTS - CONTINUED

NOTE 3. INVESTMENTS

The Plan's investments are held by Counsel Trust Company. The following table presents the fair values, as determined by quoted market price, of the investments except for the Metropolitan Life Insurance contract which is presented at contract value:

|  | 2003         |
|--|--------------|
|  | -----        |
| Enzo Biochem, Inc.*                          | \$ 1,685,349 |
| American Funds American Balanced Fund CL A*  | 1,115,300    |
| American Century Income & Growth             | 33,501       |
| Babson Value Fund*                           | 425,814      |
| American Funds Europacific Growth CL A*      | 911,523      |
| Federated Kaufmann Fund Cl K                 | 327,550      |
| Fidelity Concord Str Spartan US Eqidx        | 64,696       |
| Fidelity Contrafund Inc. Common*             | 477,631      |
| Aim Invesco Dynamics Fund                    | 37,061       |
| Aim Invesco Small Company Growth Fund        | 13,967       |
| Aim Invesco Technology Fund Investor CL      | 66,829       |
| Janus Invt Fd Sh Ben Int*                    | 571,213      |
| Neuberger & Berman Genesis Fund Trust        | 202,482      |
| Putnam New Opportunities Fd Sh Ben Int A     | 10,498       |
| American Funds Washington Mutual             |              |
| Investors Fund CL A*                         | 1,401,057    |
| American Funds US Gov't Securities Fund CL A | 167,211      |
| Metropolitan Life Ins Co - Ins Prods         | 387,198      |

\* Denotes investments representing 5% or more of net assets available for benefits at December 31, 2003.

F-7

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN

NOTES TO FINANCIAL STATEMENTS - CONTINUED

NOTE 4. INVESTMENT CONTRACT WITH INSURANCE COMPANY

The Plan has a benefit-responsive investment contract with MetLife Trust Company, National Association (MetLife). MetLife maintains the contributions in separate accounts. The accounts are credited with earnings on the underlying investments and charged for participant withdrawals and administrative expenses. The contract is included in the financial statements at contract value as reported to the Plan by Counsel Trust Company. Contract value represents contributions made under the contract, plus earnings, less participant withdrawals and

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

administrative expenses. Participants may ordinarily direct the withdrawal or transfer of all or a portion of their investment at contract value.

There are no reserves against contract value for credit risk of the contract issuer or otherwise. The average yield and crediting interest rates were approximately 3.7% for 2003.

NOTE 5. PLAN TERMINATION

Although it has not expressed any intent to do so, the Companies have the right under the Plan to discontinue their contributions at any time and to terminate the Plan subject to the provisions of ERISA.

NOTE 6. TAX STATUS

The Plan obtained its latest determination letter in February 2002 in which the Internal Revenue Service stated that the Plan was in compliance with the applicable requirements of the Internal Revenue Code.

NOTE 7. RELATED PARTY TRANSACTIONS

During 2003, the plan purchased shares of stock in Enzo Biochem, Inc., the parent company of the plan sponsor, at market prices totaling approximately \$353,696. In addition, shares were sold, at market prices totaling approximately \$139,423. At December 31, 2003 and 2002 the Plan held Enzo Biochem, Inc. stock at market prices totaling \$1,685,349 and \$1,031,265, respectively.

Fees paid by the Plan to the Plan administrators amounted to \$30,287 for the year ended December 31, 2003.

F-8

ENZO BIOCHEM, INC.  
SALARY REDUCTIONS PLAN

SCHEDULE H, ITEM 4I  
SCHEDULE OF ASSETS HELD AT END OF YEAR

E.I.N. # 13-2869332  
PLAN # 001

YEAR ENDED DECEMBER 31, 2003

| (a)   | IDENTITY OF ISSUE,<br>BORROWER, LESSOR OR<br>SIMILAR PARTY<br>(b) | DESCRIPTION OF<br>INVESTMENT INCLUDING<br>MATURITY DATE, RATE<br>OF INTEREST, COLLATERAL,<br>PAR OR MATURITY VALUE<br>(c) | COS<br>(d) |
|-------|---|---|------------|
| ----- |   |   |            |



Edgar Filing: ENZO BIOCHEM INC - Form 11-K

|   |   |               |    |
|---|---|---------------|----|
| * | Enzo Biochem, Inc.                                      | Common Stock  | ** |
|   | American Funds American Balanced Fund CL A              | Mutual Fund   | ** |
|   | American Century Income & Growth                        | Mutual Fund   | ** |
|   | Babson Value Fund                                       | Mutual Fund   | ** |
|   | American Funds Europacific Growth CL A                  | Mutual Fund   | ** |
|   | Federated Kaufmann Fund Cl K                            | Mutual Fund   | ** |
|   | Fidelity Concord Str Spartan US Eqidx                   | Mutual Fund   | ** |
|   | Fidelity Contrafund Inc. Common                         | Mutual Fund   | ** |
|   | Aim Invesco Dynamics Fund                               | Mutual Fund   | ** |
|   | Aim Invesco Small Company Growth Fund                   | Mutual Fund   | ** |
|   | Aim Invesco Technology Fund Investor CL                 | Mutual Fund   | ** |
|   | Janus Invt Fd Sh Ben Int                                | Mutual Fund   | ** |
|   | Neuberger & Berman Genesis Fund Trust                   | Mutual Fund   | ** |
|   | Putnam New Opportunities Fd Sh Ben Int A                | Mutual Fund   | ** |
|   | American Funds Washington Mutual<br>Investors Fund CL A | Mutual Fund   | ** |
|   | American Fund US Gov't Securities Fund CL A             | Mutual Fund   | ** |
|   | Metropolitan Life Ins Co - Ins Prods                    | Mutual Fund   | ** |
|   | Participant Loans                                       | 5.00% - 9.50% | ** |

- \* Party-in-interest.
- \*\* Cost information is not required.

See Independent Auditors' Report.

F-9

AUDREY WALLACH, CPA  
Certified Public Accountant

780 CYNTHIA DRIVE  
EAST MEADOW, NY 11554  
Telephone: (516) 565-6441  
E-mail: EMHAWK@aol.com

REPORT OF INDEPENDENT AUDITORS

To the Sponsor of the  
Enzo Biochem, Inc.  
Salary Reduction Profit Sharing Plan

We have audited the accompanying statements of net assets available for benefits of the Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan (the "Plan") as of December 31, 2002 and 2001, and the related statements of changes in net assets available for benefits for the year ended December 31, 2002. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2002 and 2001, and the changes in net assets available for benefits for the year ended December 31, 2002, in conformity with accounting principles generally accepted in the United States of America.

Our audits were performed for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplemental schedules of (1) assets held for investment purposes as of December 31, 2002 and (2) reportable transaction for the year ended December 31, 2002, are presented for the purpose of additional analysis and are not a required part of the basic financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. These supplemental schedules are the responsibility of the Plan's management. The supplemental schedules have been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, are fairly stated in all material respects when in relation to the basic financial statements taken as a whole.

Audrey Wallach, CPA

East Meadow, New York  
September 30, 2003

F-10

Audrey Wallach, CPA

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN  
STATEMENT OF NET ASSETS AVAILABLE FOR BENEFITS  
DECEMBER 31, 2002 AND 2001

|                        | 2002         | 2001         |
|------------------------|--------------|--------------|
|                        | -----        | -----        |
| Assets:                |              |              |
| Investments: (Note 8)  | \$ 5,615,231 | \$ 6,385,787 |
| Receivables:           |              |              |
| Employer contributions | 257,450      | 246,923      |
| Total receivables      | 257,450      | 246,923      |
|                        | -----        | -----        |
| Total assets           | 5,872,681    | 6,632,710    |
|                        | =====        | =====        |

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

Liabilities:

|                                   |              |              |
|-----------------------------------|--------------|--------------|
| Total liabilities                 | --           | --           |
| Net assets available for benefits | \$ 5,872,681 | \$ 6,632,710 |

See accompanying notes to financial statements

F-11

Audrey Wallach, CPA

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN  
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS  
YEAR ENDED DECEMBER 31, 2002

Additions to net assets attributed to:

Investment income:

|   |             |
|---|-------------|
| Interest  | \$ 7,319    |
| Net appreciation (depreciation) in<br>fair value of investments | (1,282,647) |
|   | -----       |
|   | (1,275,328) |

Contributions:

|             |         |
|-------------|---------|
| Participant | 634,148 |
| Employer    | 257,450 |
|             | -----   |
|             | 891,598 |
|             | -----   |

|                 |           |
|-----------------|-----------|
| Total additions | (383,730) |
|                 | -----     |

Deductions from net assets attributed to:

|                               |         |
|-------------------------------|---------|
| Benefits paid to participants | 337,032 |
| Administration expenses       | 39,267  |
|                               | -----   |
| Total deductions              | 376,299 |
|                               | -----   |

|                |           |
|----------------|-----------|
| Net (decrease) | (760,029) |
|----------------|-----------|

Net assets available for benefits:

|                       |              |
|-----------------------|--------------|
| Beginning of the year | 6,632,710    |
|                       | -----        |
| End of the year       | \$ 5,872,681 |
|                       | =====        |

See accompanying notes to financial statements

F-12

# Edgar Filing: ENZO BIOCHEM INC - Form 11-K

Audrey Wallach, CPA

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN  
NOTES TO FINANCIAL STATEMENTS  
DECEMBER 31, 2002

## 1. Description of the Plan

The following description of the Enzo Biochem, Inc. ("Company") Salary Reduction Profit Sharing Plan ("Plan") provides only general information. Participants should refer to the Plan agreement for a more complete description of the Plan's provisions.

Effective January 1, 1997, Enzo Labs, Inc. amended the Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan. The Plan was further amended, effective January 1, 2002, to comply with recent legislation and to ensure continued tax-favored treatment. The Plan operates under the favorable determination letter issued by the Internal Revenue Service dated February 14, 2002. Additional employers which have adopted the provisions of the Plan are Enzo clinical Labs, Inc. (formerly Enzo Labs, Inc.), Enzo Therapeutics, Inc. and Enzo Diagnostics, Inc.

The Plan is a defined contribution plan covering substantially all full-time employees who have completed three months of service and attained age 21, who are not covered under a collective bargaining agreement. It is subject to the provisions of the Employee Retirement Income Security Act (ERISA).

## 2. Summary of Significant Accounting Policies

- a. The Plan's financial statements are prepared on the accrual basis of accounting, except for cash basis of recording of benefits paid.
- b. The Plan's investments are stated at fair value. Quoted market prices are used to value investments. Shares of mutual funds are valued at the net asset value of shares held by the Plan at year end.
- c. The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly actual results may differ from those estimates.

## 3. Contributions

Each year, participants may contribute up to 17% of the participant's annual compensation, as defined in the Plan. Employee contributions vest immediately. Participants direct the investment of their contributions into various investment options offered by the Plan.

F-13

Audrey Wallach, CPA

In addition the Company makes discretionary matching contributions equal to 50%

## Edgar Filing: ENZO BIOCHEM INC - Form 11-K

of participant contributions to the extent of amounts not exceeding 10% of participants' annual compensation. In 2002 and 2001 the totals of the matching contributions were \$257,450 and \$246,923 respectively, in the form of Enzo Biochem, Inc. Company stock.

Employer contributions vest ratably over four years of service.

Forfeitures attributable to Company contribution accounts are allocated among participants eligible to share for a Plan year.

### 4. PAYMENT OF BENEFITS

Participants' benefits under the Plan are payable to participants, their beneficiaries or their estates upon the termination of employment, normal retirement, late retirement, disability, death or hardship. Benefits are payable in the form of lump-sum distributions of cash or property.

### 5. LOANS TO PARTICIPANTS

The Plan provides for loans to participants, which may be repaid through payroll deductions. Loans (i) bear a reasonable rate of interest, (ii) are secured by the participant's account, (iii) are available to all participants on a uniform and non-discriminatory basis, (iv) are limited to 50% of the participant's vested account balance or \$50,000 less the highest outstanding loan balance in the previous twelve months, (v) provide for repayment over a period not to exceed five years unless such loan is used to purchase a primary residence.

A loan will not be issued for an amount less than \$1,000.00.

### 6. TERMINATION

Although it has not expressed any intent to do so, the Company reserves the right to terminate the Plan at any time. Termination of the Plan shall result in immediate vesting of the entire amount credited to each participant. Upon termination of the Plan, the trustees shall retain sufficient assets to complete all scheduled payments due to former participants or their beneficiaries and estates.

### 7. TAX STATUS

The trust established under the plan to hold the Plan's assets is qualified pursuant to the appropriate section of the Internal Revenue Code, and accordingly, the Plan's net investment income is exempt from income taxes. The Plan has a favorable determination letter from the Internal Revenue Service. The Plan sponsor believes that the Plan qualifies and operates as designed.

F-14

Audrey Wallach, CPA

### 8 INVESTMENTS

The Company has adopted and implemented a daily valuation multi-fund family program for eligible employees. Under the daily valuation program participants are able to invest their accounts under a menu of mutual funds. A participant may (i) access his or her account value at any time and (ii) direct the investment of his or her existing account and future contributions by a toll-free number or via the internet at any time among

## Edgar Filing: ENZO BIOCHEM INC - Form 11-K

the mutual funds offered under the Plan. Under the program the automated voice response system is electronically linked to IBG to effect fund transfers. IBG provides trade confirmations for any and all buys, sells and exchanges (i.e., deposits, transfers, distributions) of funds under the daily valuation program.

FORM 5500 SCHEDULE H PART IV LINE 4i

Schedule of Assets (Held at End of Year)

| Description<br>-----                              | Current Value<br>----- |
|---|------------------------|
| Spartan US Equity Index Fund                      | 32,836                 |
| American Century Income & Growth Fund             | 16,252                 |
| American Balanced Fund Class A                    | 784,501*               |
| American US Government Securities Fund            | 143,439                |
| Invesco Dynamics Fund                             | 24,794                 |
| Invesco Small Company Growth Fund                 | 7,858                  |
| Invesco Technology Class II Fund                  | 40,098                 |
| Babson Value Fund                                 | 304,432*               |
| American EuroPacific Growth Fund                  | 625,071*               |
| Janus Fund  | 412,893*               |
| Federal Kaufmann Fund Class K                     | 209,195                |
| Neuberger Berman Genesis Trust                    | 135,767                |
| Putnam New Opportunities Fund                     | 7,086                  |
| American Washington Mutual Investors Fund Class A | 1,059,846*             |
| Fidelity FMMT Retirement Money Market Fund        | 272,559                |
| Fidelity Contrafund                               | 331,444*               |
| Enzo Biochem, Inc. Common Stock                   | 1,031,265*             |
| Participant Loans                                 | 174,741                |
| Cash  | 1,154                  |
|   | 5,615,231              |
|   | =====                  |

\* Represents more than 5% of total assets.

F-15

Audrey Wallach, CPA

### 9. NON-EXEMPT TRANSACTIONS

It was noted that there were unintentional delays by the Company in remitting employee deferrals to the trust in amounts totaling \$88,234. Accordingly, the Plan should be reimbursed for the \$137 in lost earnings.

F-16

Audrey Wallach, CPA

Edgar Filing: ENZO BIOCHEM INC - Form 11-K

ENZO BIOCHEM, INC.  
SALARY REDUCTION PROFIT SHARING PLAN

SCHEDULE G, PART III FORM 5500  
NONEXEMPT TRANSACTIONS  
FOR THE YEAR ENDED DECEMBER 31, 2002

(a) Identity of party involved

Enzo Biochem, Inc.

(b) Relationship to plan

Plan Sponsor

(c) Description of transactions including maturity date, rate of interest

Employee deferral and loan payments not deposited with the Plan in a timely manner. Interest at 6%.

(h) Cost of asset

\$137

See accompanying notes to financial statements

F-17

SIGNATURES

THE PLAN. Pursuant to the requirements of the Securities Exchange Act of 1934, a trustee of the below named employee benefit plan has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

Enzo Biochem, Inc.  
Salary Reduction Profit Sharing Plan

Date: June 25, 2004

/s/ Herbert Bass

-----  
By: Herbert Bass  
Trustee

=====